Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SOX in Perioperative Treatment of Resectable Gastric or GEJ Cancer
NCT07522151Phase 3Recruiting
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of adebrelimab in gastric cancer (GC), gastroesophageal junction cancer. Started May 2026; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT07522151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07522151.